Pioneering Epigenetic Medicine
Epigenic Therapeutics’ EPIREG® proprietary technology platform employs its own artificial intelligence (AI) algorithms to explore and obtain innovative CRISPR-Cas components to regulate target gene(s) expression without changing the DNA sequence. Combining a patented lipid nanoparticle (LNP) delivery system, our platform has been proven to precisely and efficiently deliver medicine to targeted cells and tissues in metabolic, cardiovascular, viral hepatitis, ocular, oncology and rare disease models.
Our Culture
-
Vision
To commit to the development of safe and sustainable epigenetic therapy, help people improve the quality of life
-
Mission
To pioneer gene regulation-based biotherapeutics in order to benefit patients worldwide
-
Values
Respect to talents, revere for life, strive to excellence, and innovate for advancement
Our History
EPI-001(PCSK9) IIT approved
Investors
Honor
-
Forbes Asia 100 To Watch 2024
-
Outstanding Innovative Drug Pipeline Award in 2024
-
Top 15 Emerging Innovative Drug Enterprises for China in 2023
-
BSA Rising Star in 2023
-
Top 100 Most Valuable Pharmaceutical Innovations for China between 2022-2023
-
Shanghai High-Tech Enterprise